Based on our hypothesis, the interaction between CLRs and the fungal mycobiome is the dominant component of the antifungal immune response in bladder cancer and the subsequent anti-tumor immune response and determines the efficacy of ICB therapy. This evidence concerns the gene LARS1 and urinary bladder cancer.